Literature DB >> 7427045

Tumour thickness and the site and time of first recurrence in cutaneous malignant melanoma (stage I).

G W Milton, H M Shaw, G A Farago, W H McCarthy.   

Abstract

A study was made of 326 patients first treated for clinical stage I cutaneous malignant melanoma by a wide excision (with or without split-skin graft) but no nodal dissection and who subsequently developed recurrence of their disease. Thick lesions recurred far more frequently than very thin lesions, although evidence of partial regression in very thin lesions conferred upon the latter a liability to metastasize. Thicker lesions first recurred predominantly in the vicinity of the scar of primary lesion excision whilst very thin lesions first recurred either at regional lymph nodes or at remote sites. The disease-free interval fell with increasing tumour thickness. As a result of this, local first recurrences developed more rapidly than remote first recurrences. The cumulative 10-year survival rate for patients with local first recurrences was, however, significantly higher than for patients with remote first recurrences, as the survival period after local first recurrence was considerably longer than after remote first recurrence. We conclude that tumour thickness is an easily measured, objective predictor of the site and time of first recurrence from melanoma. Thus, by facilitating early detection of first metastases, it may be possible to prolong survival time.

Entities:  

Mesh:

Year:  1980        PMID: 7427045     DOI: 10.1002/bjs.1800670804

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  9 in total

1.  Molecular clonality of in-transit melanoma metastasis.

Authors:  T Nakayama; B Taback; R Turner; D L Morton; D S Hoon
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  Surgical management of primary melanoma.

Authors:  D Costello; A Powers; J Lynn; C W Cruse; D Reintgen
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

3.  Thin (less than or equal to 1 mm) melanomas of the extremities are biologically favorable lesions not influenced by regression.

Authors:  H J Wanebo; P H Cooper; R W Hagar
Journal:  Ann Surg       Date:  1985-04       Impact factor: 12.969

4.  Clinical features of superficial spreading melanomas with zones of regression.

Authors:  B M Czarnetzki; M Denter; E B Bröcker; P Rümke; V Krieg; F Vakilzadeh; E Macher
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

5.  A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia.

Authors:  C M Balch; S J Soong; G W Milton; H M Shaw; V J McGovern; T M Murad; W H McCarthy; W A Maddox
Journal:  Ann Surg       Date:  1982-12       Impact factor: 12.969

6.  Expression of the p53 protein in malignant melanomas as a prognostic indicator.

Authors:  M Yamamoto; H Takahashi; K Saitoh; T Horikoshi; M Takahashi
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

7.  Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial.

Authors:  C M Balch; M M Urist; C P Karakousis; T J Smith; W J Temple; K Drzewiecki; W R Jewell; A A Bartolucci; M C Mihm; R Barnhill
Journal:  Ann Surg       Date:  1993-09       Impact factor: 12.969

8.  Lethal "thin" malignant melanoma. Identifying patients at risk.

Authors:  C L Slingluff; R T Vollmer; D S Reintgen; H F Seigler
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

9.  A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II).

Authors:  C M Balch; S J Soong; T M Murad; A L Ingalls; W A Maddox
Journal:  Ann Surg       Date:  1981-03       Impact factor: 12.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.